Skip to main content
Clinical Trials/NL-OMON56845
NL-OMON56845
Not yet recruiting
Not Applicable

Primary percutaneous stenting of the bile ducts in patients with resectable perihilar cholangiocarcinoma - a pilot study - TESLA 2 pilot

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Bile duct cancer
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
12
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Written informed consent must be given according to ICH/GCP, and
  • national/local regulations.
  • Resectable pCCA on imaging with histopathological confirmation or high
  • clinical suspicion (as determined by the multidisciplinary hepatobiliary team).
  • Hyperbilirubinemia (a combination of a total bilirubin level \>50 mmol/l.
  • Age above 18 years

Exclusion Criteria

  • Fluctuation or spontaneous decrease of a total bilirubin level before start
  • of any treatment suggesting potential benign origin.
  • Patients who underwent previous drainage procedures endoscopically or
  • percutaneously with an internalized biliary catheter.
  • Clinical signs of cholangitis. Cholangitis was defined as the presence of
  • both fever (i.e. body temperature \>38\.5°C) combined with leucocytosis (i.e. \>\=10
  • \*109/L) without clinical or radiological evidence of acute cholecystitis
  • Uncorrectable coagulation disorder.
  • Uncorrectable contrast allergy.

Outcomes

Primary Outcomes

Not specified

Similar Trials